Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1552652/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860897674690560 |
|---|---|
| author | Zhi-Bin Wang Zhi-Bin Wang Zhi-Bin Wang De-Hua Liao Guang Lei Zhao-Qian Liu Zhao-Qian Liu Nayiyuan Wu Nayiyuan Wu Jing Wang Jing Wang |
| author_facet | Zhi-Bin Wang Zhi-Bin Wang Zhi-Bin Wang De-Hua Liao Guang Lei Zhao-Qian Liu Zhao-Qian Liu Nayiyuan Wu Nayiyuan Wu Jing Wang Jing Wang |
| author_sort | Zhi-Bin Wang |
| collection | DOAJ |
| format | Article |
| id | doaj-art-4522fa331c434bcd85c2a8f40dd4829f |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-4522fa331c434bcd85c2a8f40dd4829f2025-02-10T09:08:27ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-02-011610.3389/fphar.2025.15526521552652Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume IIZhi-Bin Wang0Zhi-Bin Wang1Zhi-Bin Wang2De-Hua Liao3Guang Lei4Zhao-Qian Liu5Zhao-Qian Liu6Nayiyuan Wu7Nayiyuan Wu8Jing Wang9Jing Wang10Hunan Key Laboratory of Cancer Metabolism, Central South University/Hunan Cancer Hospital, Changsha, Hunan, ChinaPublic Service Platform of Tumor Organoids Technology, Hunan Gynecological Tumor Clinical Research Center, Changsha, Hunan, ChinaDepartment of Pharmacy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, ChinaDepartment of Pharmacy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, ChinaDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesHunan Key Laboratory of Pharmacogenetics, Department of Clinical Pharmacology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaInstitute of Clinical Pharmacology, Engineering Research Center for Applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha, Hunan, ChinaHunan Key Laboratory of Cancer Metabolism, Central South University/Hunan Cancer Hospital, Changsha, Hunan, ChinaPublic Service Platform of Tumor Organoids Technology, Hunan Gynecological Tumor Clinical Research Center, Changsha, Hunan, ChinaHunan Key Laboratory of Cancer Metabolism, Central South University/Hunan Cancer Hospital, Changsha, Hunan, ChinaPublic Service Platform of Tumor Organoids Technology, Hunan Gynecological Tumor Clinical Research Center, Changsha, Hunan, Chinahttps://www.frontiersin.org/articles/10.3389/fphar.2025.1552652/fullovarian cancertargeted medicationimmunomodulatorydrug resistancePARP inhibitorsanti-angiogenic drugs |
| spellingShingle | Zhi-Bin Wang Zhi-Bin Wang Zhi-Bin Wang De-Hua Liao Guang Lei Zhao-Qian Liu Zhao-Qian Liu Nayiyuan Wu Nayiyuan Wu Jing Wang Jing Wang Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II Frontiers in Pharmacology ovarian cancer targeted medication immunomodulatory drug resistance PARP inhibitors anti-angiogenic drugs |
| title | Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II |
| title_full | Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II |
| title_fullStr | Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II |
| title_full_unstemmed | Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II |
| title_short | Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II |
| title_sort | editorial ovarian cancer targeted medication parp inhibitors anti angiogenic drugs immunotherapy and more volume ii |
| topic | ovarian cancer targeted medication immunomodulatory drug resistance PARP inhibitors anti-angiogenic drugs |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1552652/full |
| work_keys_str_mv | AT zhibinwang editorialovariancancertargetedmedicationparpinhibitorsantiangiogenicdrugsimmunotherapyandmorevolumeii AT zhibinwang editorialovariancancertargetedmedicationparpinhibitorsantiangiogenicdrugsimmunotherapyandmorevolumeii AT zhibinwang editorialovariancancertargetedmedicationparpinhibitorsantiangiogenicdrugsimmunotherapyandmorevolumeii AT dehualiao editorialovariancancertargetedmedicationparpinhibitorsantiangiogenicdrugsimmunotherapyandmorevolumeii AT guanglei editorialovariancancertargetedmedicationparpinhibitorsantiangiogenicdrugsimmunotherapyandmorevolumeii AT zhaoqianliu editorialovariancancertargetedmedicationparpinhibitorsantiangiogenicdrugsimmunotherapyandmorevolumeii AT zhaoqianliu editorialovariancancertargetedmedicationparpinhibitorsantiangiogenicdrugsimmunotherapyandmorevolumeii AT nayiyuanwu editorialovariancancertargetedmedicationparpinhibitorsantiangiogenicdrugsimmunotherapyandmorevolumeii AT nayiyuanwu editorialovariancancertargetedmedicationparpinhibitorsantiangiogenicdrugsimmunotherapyandmorevolumeii AT jingwang editorialovariancancertargetedmedicationparpinhibitorsantiangiogenicdrugsimmunotherapyandmorevolumeii AT jingwang editorialovariancancertargetedmedicationparpinhibitorsantiangiogenicdrugsimmunotherapyandmorevolumeii |